IMARA(US:IMRA)2025-05-14 20:10Financial Performance - Enliven Therapeutics reported a net loss of $28.5 million for Q1 2025, compared to a net loss of $22.7 million in Q1 2024, reflecting an increase of 25% year-over-year[7]. - General and administrative expenses for Q1 2025 were $6.8 million, compared to $6.0 million in Q1 2024, marking an increase of 13.3%[7]. - The company reported total operating expenses of $31.7 million for Q1 2025, compared to $26.0 million for Q1 2024, representing a 22% increase[7]. Research and Development - Research and development expenses for Q1 2025 were $24.9 million, up from $20.0 million in Q1 2024, indicating a 24.5% increase[7]. - In the Phase 1 ENABLE clinical trial of ELVN-001, 44% of evaluable patients achieved major molecular response (MMR) by 24 weeks[3]. - The trial enrolled 74 patients, with 82% remaining on study and a median treatment duration of approximately 26 weeks[3]. - Enliven plans to start a pivotal trial for ELVN-001 in 2026, focusing on clinical execution for the remainder of the year[2]. - The company intends to explore strategic alternatives for the ELVN-002 program and does not plan to pursue its development beyond 2025[7]. - Enliven will present updated data from the ENABLE trial at the EHA 2025 Congress in June 2025[3]. Cash Position - The company had cash, cash equivalents, and marketable securities totaling $289.6 million as of March 31, 2025, expected to provide a cash runway into late 2027[7].